

Title: Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2)

Decision: The Centers for Medicare & Medicaid Services (CMS) has updated National Coverage Determination (NCD) 20.32 for Transcatheter Aortic Valve Replacement (TAVR) to:

- 1) cover TAVR for symptomatic severe aortic valve stenosis (or aortic stenosis (AS)) without the coverage with evidence development (CED) requirement;
- 2) expand coverage of TAVR to asymptomatic severe AS with CED;
- 3) revise coverage criteria related to pre-procedural patient assessment, intraoperative requirements, and operator and hospital procedural volume requirements.

What this means: Transcatheter Aortic Valve Replacement (TAVR) for the treatment of symptomatic severe aortic stenosis may now be covered outside of a CMS-approved clinical study when applicable coverage criteria in the Medicare NCD are met. TAVR for the treatment of asymptomatic severe aortic stenosis may now be covered for individuals who are enrolled in a CMS-approved clinical study and who meet the criteria outlined in the Medicare NCD. Please refer to the final decision memo for all coverage criteria.

Effective: September 10, 2026

This announcement can be found at: [Transcatheter Aortic Valve Replacement \(TAVR\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2422_90242 IR Approved 07/2015
Y0095_90242 IR Approved 01/2026